 Drug Costs
"Drug Costs" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The amount that a health care institution or organization pays for its drugs. It is one component of the final price that is charged to the consumer (FEES, PHARMACEUTICAL or PRESCRIPTION FEES).
| Descriptor ID |
D016527
|
| MeSH Number(s) |
N03.219.151.400.350 N05.300.375.300
|
| Concept/Terms |
Drug Costs- Drug Costs
- Cost, Drug
- Costs, Drug
- Drug Cost
|
Below are MeSH descriptors whose meaning is more general than "Drug Costs".
Below are MeSH descriptors whose meaning is more specific than "Drug Costs".
This graph shows the total number of publications written about "Drug Costs" by people in this website by year, and whether "Drug Costs" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 0 | 1 | 1 | | 1994 | 0 | 2 | 2 | | 1995 | 0 | 1 | 1 | | 1997 | 0 | 1 | 1 | | 1998 | 0 | 2 | 2 | | 1999 | 0 | 2 | 2 | | 2000 | 1 | 1 | 2 | | 2001 | 1 | 0 | 1 | | 2002 | 0 | 3 | 3 | | 2003 | 1 | 3 | 4 | | 2004 | 1 | 0 | 1 | | 2005 | 1 | 2 | 3 | | 2006 | 1 | 2 | 3 | | 2007 | 0 | 2 | 2 | | 2008 | 2 | 5 | 7 | | 2009 | 0 | 2 | 2 | | 2011 | 0 | 1 | 1 | | 2012 | 2 | 5 | 7 | | 2013 | 0 | 3 | 3 | | 2014 | 3 | 3 | 6 | | 2015 | 0 | 3 | 3 | | 2016 | 3 | 4 | 7 | | 2017 | 5 | 0 | 5 | | 2018 | 0 | 4 | 4 | | 2019 | 3 | 0 | 3 | | 2020 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Drug Costs" by people in Profiles.
-
Synnott PG, McQueen RB, Ollendorf DA, Campbell JD, Pearson SD. The Effectiveness and Value of Rivaroxaban and Icosapent Ethyl as Additive Therapies for Cardiovascular Disease. J Manag Care Spec Pharm. 2020 Jun; 26(6):782-785.
-
Carroll JK, Farah S, Fortuna RJ, Lanigan AM, Sanders M, Venci JV, Fiscella K. Addressing Medication Costs During Primary Care Visits: A Before-After Study of Team-Based Training. Ann Intern Med. 2019 05 07; 170(9_Suppl):S46-S53.
-
Feinstein JA, Hall M, Antoon JW, Thomson J, Flores JC, Goodman DM, Cohen E, Azuine R, Agrawal R, Houtrow AJ, DeCourcey DD, Kuo DZ, Coller R, Gaur DS, Berry JG. Chronic Medication Use in Children Insured by Medicaid: A Multistate Retrospective Cohort Study. Pediatrics. 2019 04; 143(4).
-
Smith GH, Shore S, Allen LA, Markham DW, Mitchell AR, Moore M, Morris AA, Speight CD, Dickert NW. Discussing Out-of-Pocket Costs With Patients: Shared Decision Making for Sacubitril-Valsartan in Heart Failure. J Am Heart Assoc. 2019 01 08; 8(1):e010635.
-
Campbell JD, Kaló Z. Fair global drug pricing. Expert Rev Pharmacoecon Outcomes Res. 2018 Dec; 18(6):581-583.
-
Schnippel K, Firnhaber C, Page-Shipp L, Sinanovic E. Impact of adverse drug reactions on the incremental cost-effectiveness of bedaquiline for drug-resistant tuberculosis. Int J Tuberc Lung Dis. 2018 08 01; 22(8):918-925.
-
Campbell JD, Belozeroff V, Whittington MD, Rubin RJ, Raggi P, Briggs AH. Prices For Common Cardiovascular Drugs In The US Are Not Consistently Aligned With Value. Health Aff (Millwood). 2018 08; 37(8):1298-1305.
-
Whittington MD, McQueen RB, Campbell JD. Considerations for Cost-effectiveness Analysis of Curative Pediatric Therapies. JAMA Pediatr. 2018 05 01; 172(5):409-410.
-
Whittington MD, Knupp KG, Vanderveen G, Kim C, Gammaitoni A, Campbell JD. The direct and indirect costs of Dravet Syndrome. Epilepsy Behav. 2018 03; 80:109-113.
-
Schnippel K, Firnhaber C, Conradie F, Ndjeka N, Sinanovic E. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis. Appl Health Econ Health Policy. 2018 Feb; 16(1):43-54.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|